請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26346完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 廖淑貞 | |
| dc.contributor.author | Hui-Chun Wu | en |
| dc.contributor.author | 吳慧君 | zh_TW |
| dc.date.accessioned | 2021-06-08T07:07:05Z | - |
| dc.date.copyright | 2008-09-11 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-08-21 | |
| dc.identifier.citation | 1. Buchanan, K. L., and J. W. Murphy. 1998. What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis 4:71-83.
2. Buschke, A. 1895. U¨ ber eine durch Coccidien Hervergerufene Krankheit des menschen. . Dtsch. Med. Wochenschr. 21:14. 3. Busse, O. 1894. U¨ ber parasita¨re zelleinschlu¨sse und ihre zu¨chtung. . Zentralbl. Bakteriol. 16:175-180. 4. Casadevall, A., and J. R. Perfect. 1998. Cryptococcus neoformans. ASM Press, Washington, DC. 5. Chang, W. N., C. R. Huang, C. B. Lei, P. Y. Lee, C. C. Chien, H. W. Chang, C. S. Chang, and C. H. Lu. 2004. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole. Jpn J Infect Dis 57:113-5. 6. Chang, Y. C., and K. J. Kwon-Chung. 1994. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 14:4912-9. 7. Chaturvedi, S., B. Rodeghier, J. Fan, C. M. McClelland, B. L. Wickes, and V. Chaturvedi. 2000. Direct PCR of Cryptococcus neoformans MATalpha and MATa pheromones to determine mating type, ploidy, and variety: a tool for epidemiological and molecular pathogenesis studies. J Clin Microbiol 38:2007-9. 8. Chayakulkeeree, M., and J. R. Perfect. 2006. Cryptococcosis. Infect Dis Clin North Am 20:507-44, v-vi. 9. Chen, S. C., M. Muller, J. Z. Zhou, L. C. Wright, and T. C. Sorrell. 1997. Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J Infect Dis 175:414-20. 10. Chen, Y. C., S. C. Chang, C. C. Shih, C. C. Hung, K. T. Luhbd, Y. S. Pan, and W. C. Hsieh. 2000. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis 36:175-83. 11. Cherniak, R., E. Reiss, M. E. Slodki, R. D. Plattner, and S. O. Blumer. 1980. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol Immunol 17:1025-32. 12. Clancy, C. J., M. H. Nguyen, R. Alandoerffer, S. Cheng, K. Iczkowski, M. Richardson, and J. R. Graybill. 2006. Cryptococcus neoformans var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors. Microbiology 152:2247-55. 13. Coenjaerts, F. E. 2006. The sixth international conference on cryptococcus and cryptococcosis. FEMS Yeast Res 6:312-7. 14. Cogliati, M., M. C. Esposto, G. Liberi, A. M. Tortorano, and M. A. Viviani. 2007. Cryptococcus neoformans typing by PCR fingerprinting using (GACA)4 primers based on C. neoformans genome project data. J Clin Microbiol 45:3427-30. 15. Cox, G. M., H. C. McDade, S. C. Chen, S. C. Tucker, M. Gottfredsson, L. C. Wright, T. C. Sorrell, S. D. Leidich, A. Casadevall, M. A. Ghannoum, and J. R. Perfect. 2001. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol 39:166-75. 16. Cox, G. M., J. Mukherjee, G. T. Cole, A. Casadevall, and J. R. Perfect. 2000. Urease as a virulence factor in experimental cryptococcosis. Infect Immun 68:443-8. 17. Dromer, F., E. Gueho, O. Ronin, and B. Dupont. 1993. Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol 31:359-63. 18. Emmons, C. W. 1955. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg 62:227-32. 19. Enache-Angoulvant, A., J. Chandenier, F. Symoens, P. Lacube, J. Bolognini, C. Douchet, J. L. Poirot, and C. Hennequin. 2007. Molecular identification of Cryptococcus neoformans serotypes. J Clin Microbiol 45:1261-5. 20. Franzot, S. P., J. Mukherjee, R. Cherniak, L. C. Chen, J. S. Hamdan, and A. Casadevall. 1998. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun 66:89-97. 21. Franzot, S. P., I. F. Salkin, and A. Casadevall. 1999. Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 37:838-40. 22. Ganendren, R., E. Carter, T. Sorrell, F. Widmer, and L. Wright. 2006. Phospholipase B activity enhances adhesion of Cryptococcus neoformans to a human lung epithelial cell line. Microbes Infect 8:1006-15. 23. Gomez-Lopez, A., O. Zaragoza, M. Dos Anjos Martins, M. C. Melhem, J. L. Rodriguez-Tudela, and M. Cuenca-Estrella. 2008. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin Microbiol Infect 14:727-30. 24. Grover, N., S. R. Nawange, J. Naidu, S. M. Singh, and A. Sharma. 2007. Ecological niche of Cryptococcus neoformans var. grubii and Cryptococcus gattii in decaying wood of trunk hollows of living trees in Jabalpur City of Central India. Mycopathologia 164:159-70. 25. Guillot, L., S. F. Carroll, M. Badawy, and S. T. Qureshi. 2008. Cryptococcus neoformans induces IL-8 secretion and CXCL1 expression by human bronchial epithelial cells. Respir Res 9:9. 26. Hsueh, P. R., Y. J. Lau, Y. C. Chuang, J. H. Wan, W. K. Huang, J. M. Shyr, J. J. Yan, K. W. Yu, J. J. Wu, W. C. Ko, Y. C. Yang, Y. C. Liu, L. J. Teng, C. Y. Liu, and K. T. Luh. 2005. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 49:512-7. 27. Ikeda, R., T. Shinoda, Y. Fukazawa, and L. Kaufman. 1982. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol 16:22-9. 28. Ito-Kuwa, S., K. Nakamura, S. Aoki, and V. Vidotto. 2007. Serotype identification of Cryptococcus neoformans by multiplex PCR. Mycoses 50:277-81. 29. Jacobson, E. S., and S. B. Tinnell. 1993. Antioxidant function of fungal melanin. J Bacteriol 175:7102-4. 30. Khan, Z. U., H. S. Randhawa, T. Kowshik, A. Chowdhary, and R. Chandy. 2007. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J Antimicrob Chemother 60:312-6. 31. Kidd, S. E., F. Hagen, R. L. Tscharke, M. Huynh, K. H. Bartlett, M. Fyfe, L. Macdougall, T. Boekhout, K. J. Kwon-Chung, and W. Meyer. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 101:17258-63. 32. Kwon-Chung, K. J., and J. E. Bennett. 1978. Distribution of alpha and alpha mating types of Cryptococcus neoformans among natural and clinical isolates. Am J Epidemiol 108:337-40. 33. Kwon-Chung KJ, B. T., Fell JW. . 2002. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus. Taxon 51:804-6. 34. Kwon-Chung, K. J., J. C. Edman, and B. L. Wickes. 1992. Genetic association of mating types and virulence in Cryptococcus neoformans. Infect Immun 60:602-5. 35. Kwon-Chung KJ, H. W. 1981 Sexuality and pathogenicity of Filobasidiella neoformans ( Cryptococcus neoformans ). . Sexuality and pathogenicity of fungi. Paris: Masson:243-50. 36. Kwon-Chung, K. J., and A. Varma. 2006. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res 6:574-87. 37. Levitz, S. M. 1991. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 13:1163-9. 38. Lin, X., and J. Heitman. 2006. The biology of the Cryptococcus neoformans species complex. Annu Rev Microbiol 60:69-105. 39. Litvintseva, A. P., L. Kestenbaum, R. Vilgalys, and T. G. Mitchell. 2005. Comparative analysis of environmental and clinical populations of Cryptococcus neoformans. J Clin Microbiol 43:556-64. 40. Loftus, B. J., E. Fung, P. Roncaglia, D. Rowley, P. Amedeo, D. Bruno, J. Vamathevan, M. Miranda, I. J. Anderson, J. A. Fraser, J. E. Allen, I. E. Bosdet, M. R. Brent, R. Chiu, T. L. Doering, M. J. Donlin, C. A. D'Souza, D. S. Fox, V. Grinberg, J. Fu, M. Fukushima, B. J. Haas, J. C. Huang, G. Janbon, S. J. Jones, H. L. Koo, M. I. Krzywinski, J. K. Kwon-Chung, K. B. Lengeler, R. Maiti, M. A. Marra, R. E. Marra, C. A. Mathewson, T. G. Mitchell, M. Pertea, F. R. Riggs, S. L. Salzberg, J. E. Schein, A. Shvartsbeyn, H. Shin, M. Shumway, C. A. Specht, B. B. Suh, A. Tenney, T. R. Utterback, B. L. Wickes, J. R. Wortman, N. H. Wye, J. W. Kronstad, J. K. Lodge, J. Heitman, R. W. Davis, C. M. Fraser, and R. W. Hyman. 2005. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 307:1321-4. 41. McFadden, D. C., M. De Jesus, and A. Casadevall. 2006. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem 281:1868-75. 42. Meyer, W., A. Castaneda, S. Jackson, M. Huynh, and E. Castaneda. 2003. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9:189-95. 43. Meyer, W., K. Marszewska, M. Amirmostofian, R. P. Igreja, C. Hardtke, K. Methling, M. A. Viviani, A. Chindamporn, S. Sukroongreung, M. A. John, D. H. Ellis, and T. C. Sorrell. 1999. Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardize techniques on which to base a detailed epidemiological survey. Electrophoresis 20:1790-9. 44. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 8:515-48. 45. Nakamura, Y., R. Kano, S. Watanabe, and A. Hasegawa. 2000. Molecular analysis of CAP59 gene sequences from five serotypes of Cryptococcus neoformans. J Clin Microbiol 38:992-5. 46. Nosanchuk, J. D., and A. Casadevall. 2003. The contribution of melanin to microbial pathogenesis. Cell Microbiol 5:203-23. 47. Noverr, M. C., G. M. Cox, J. R. Perfect, and G. B. Huffnagle. 2003. Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production. Infect Immun 71:1538-47. 48. Odom, A., S. Muir, E. Lim, D. L. Toffaletti, J. Perfect, and J. Heitman. 1997. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J 16:2576-89. 49. Okabayashi, K., A. Hasegawa, and T. Watanabe. 2007. Microreview: capsule-associated genes of Cryptococcus neoformans. Mycopathologia 163:1-8. 50. Okabayashi, K., R. Kano, Y. Nakamura, S. Watanabe, and A. Hasegawa. 2006. Capsule-associated genes of serotypes of Cryptococcus neoformans, especially serotype AD. Med Mycol 44:127-32. 51. Okabayashi, K., R. Kano, S. Watanabe, and A. Hasegawa. 2005. Expression of capsule-associated genes of Cryptococcus neoformans. Mycopathologia 160:1-7. 52. Olszewski, M. A., M. C. Noverr, G. H. Chen, G. B. Toews, G. M. Cox, J. R. Perfect, and G. B. Huffnagle. 2004. Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol 164:1761-71. 53. Rhodes, J. C., I. Polacheck, and K. J. Kwon-Chung. 1982. Phenoloxidase activity and virulence in isogenic strains of Cryptococcus neoformans. Infect Immun 36:1175-84. 54. Sanfelice, F. 1894. Contributo alla morfologia e biologia dei blastomiceti che sisviluppano nei succhi di alcuni frutti. Ann. Igien. 4:463-465. 55. Speed, B., and D. Dunt. 1995. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 21:28-34; discussion 35-6. 56. Stephen, C., S. Lester, W. Black, M. Fyfe, and S. Raverty. 2002. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J 43:792-4. 57. Wang, Y., and A. Casadevall. 1994. Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother 38:2648-50. 58. Wayne, P. 2002. Standards Reference method for broth microdilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, . National Committee for Clinical Laboratory. 59. Williamson, P. R. 1994. Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans: identification as a laccase. J Bacteriol 176:656-64. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26346 | - |
| dc.description.abstract | 新型隱球菌(Cryptococcus neoformans),為具有莢膜的黴菌,可行出芽生殖,乃臨床上重要的伺機性病原菌,尤其好發於免疫低下者如愛滋病患者及接受器官移植或癌症化療等的族群中。新型隱球菌的感染大多藉由吸入空氣中的孢子或隱球菌細胞所造成,肺部則是初期感染的部位。新型隱球菌可透過血行性擴散至中樞神經系統,嚴重時可引發隱球菌性腦膜炎、甚至造成死亡,乃愛滋病患者常見的死因之一。新型隱球菌可根據莢膜抗原特異性區分為不同血清型,血清型A、D及AD屬於Cryptococcus neoformans;而血清型B、C則於近年獨立為新的一個種(species) Cryptococcus gattii。Cryptococcus neoformans的感染遍及全世界,且多與鴿糞及免疫低下的族群相關,而Cryptococcus gattii則被認為分佈於熱帶及亞熱帶地區,近年更有感染免疫健全者(immunocompetent)的病例出現,而新型隱球菌的發生率及各種型別的盛行率調查,在世界各地均有之。有鑑於此,本篇論文即欲探討臺灣地區造成感染的隱球菌菌株類別及其分子特性,進行包括分型(typing)、毒力因子表現,與藥物感受性之研究。我們發現,目前造成臺灣臨床上感染的菌株仍以Cryptococcus neoformans血清型A/ VNI/ VN6, 交配型α為主流,且多項毒力因子表現各有差異,而藥物感受性大致上仍屬良好,無抗藥性菌株出現。所有的臨床菌株皆可產生黑色素及具備尿素酶活性。在本研究中亦發現臨床菌株與環境菌株及實驗室標準菌株相較之下,具有較高的磷脂酶活性。我們選用磷脂酶活性最高的臨床菌株59及磷脂酶活性最低的臨床菌株24,進一步分析其他毒力因子表現與所引起的宿主反應是否有差異。菌株59與24於37℃的生長速率相似,在細胞模式中發現,菌株59對肺部上皮細胞A549具有較高的吸附性(Cell adhesion ability),並可造成較大的細胞毒性(cytotoxicity),但59的莢膜基因表現量則低於24。顯示磷脂酶活性可能在引起肺部細胞感染的過程中扮演關鍵的角色,可增加對細胞的吸附性,而其對細胞吸附性的影響甚至可能凌駕於莢膜的影響之上,是一項重要的毒力因子。 | zh_TW |
| dc.description.abstract | The encapsulated budding yeast, Cryptococcus neoformans, has become a critically important opportunistic pathogen in individuals who are immunocompromised in all parts of the world. Cryptococcosis is initiated by fungal spores or cells deposited in the alveoli of the lungs and life-threatening for immunocompromised individuals when Cryptococcus cells disseminate from the lungs to major organs of the body, such as central nervous system (CNS). Cryptococcal meningitis is the most common fungal infection of the CNS in AIDS patients and the etiologic agent of 99% of these cases is Cryptococcus neoformans var. grubii /serotype A. The serotype classification is based on the agglutination reactions of the capsular polysaccharide antigens, which can be determined by using absorbed rabbit sera. The serotype A, D and the hybrid AD strains belong to C. neoformans whereas serotype B and C have been classdied as Cryptococcus gattii. C. neoformans is primarily found worldwide associated with excreta from pigeons and in tree hollows. C. gattii was primarily found in tropical and subtropical regions for years until it cause endemic outbreak in immunocompetent humans on Vancouver Island in Canada. According to molecular methods, such as URA5-RFLP, M13 PCR fingerprinting, C. neoformans and C. gattii are further classified into four molecular types for each species: VNI-VNIV and VGI-VGIV respectively. There are several virulence factor which have been explored including 37℃ growth ability, melanin production, capsule formation, phospholipase and urease, etc.
In this study, we analyze the molecular types and mating type of 125 clinical isolates in Taiwan from 1999 to 2004. We also investigate the virulence factors, antifugal susceptibilities, and host response in different clinical isolates. 123 of the 125 isolates were C. neoformans serotype A while the other two were C. gattii serotype B.122 of the 123 serotype A strains belongs to VNI genotype and the remain one is VNII. Two C. gattii strains are both VGI genotype. All isolates were susceptible to antifungal drugs and exhibited mating typeα. Virulence factors expression was different among these clinical isolates. All of the clinical isolates all were urease and melanin positive. Most of them were hyperphospholipase. We further analyzed the host response to hyperphospholipase strain 59 and hypophospholipase strain 24 in cell-line model and find that 59 presented greater cell adhesion ability to lung epithelial cell A549 and induced more cytotoxicty. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T07:07:05Z (GMT). No. of bitstreams: 1 ntu-97-R95424015-1.pdf: 1528101 bytes, checksum: 479572a0afc22fe8eb9831151af874b5 (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 誌謝……………………………………………………………………i
中文摘要………………………………………………………………Ⅰ 英文摘要………………………………………………………………Ⅱ 目錄……………………………………………………………………一 表目錄…………………………………………………………………三 圖目錄…………………………………………………………………四 附錄目錄………………………………………………………………六 第一章 緒論……………………………………………………………1 第一節 新型隱球菌(Cryptococcis neoformans)介紹………………………1 第二節 研究動機與目的……………………………………………………5 第三節 實驗流程……………………………………………………………6 第二章 研究方法與材料………………………………………7 第一節 實驗材料……………………………………………………………7 第二節 實驗方法……………………………………………………………10 (一) 以分生方法調查新型隱球菌臨床菌株之分型(molecular typing)………………………………10 (二) 新型隱球菌臨床菌株之毒力因子分析……………………17 (三) 藥物感受性試驗…………………22 (四) 宿主反應試驗(host response)……………26 第三章 實驗結果……………………29 第一節 新型隱球菌臨床菌株之來源……………………………29 第二節 以分生方法調查新型隱球菌臨床菌株之分型……………………30 第三節 新型隱球菌臨床菌株之毒力因子分析……………………………33 第四節 新型隱球菌臨床菌株對抗真菌藥物之感受性……………………36 第四章 結論與討論……………………………………………37 第一節 調查新型隱球菌臨床菌株之分型與分類……………………37 第二節 新型隱球菌臨床菌株之毒力因子分析…………………………41 第三節 新型隱球菌臨床菌株對抗真菌藥物之感受性……………43 第四節 結論…………………………………………………………………44 第五章 表………………………………………………………………46 第六章 圖……………………………………………………59 第七章 附錄…………………………………72 第八章 參考文獻…………………………………74 | |
| dc.language.iso | zh-TW | |
| dc.subject | 毒力因子 | zh_TW |
| dc.subject | 新型隱球菌 | zh_TW |
| dc.subject | 分型 | zh_TW |
| dc.subject | typing | en |
| dc.subject | virulence factor | en |
| dc.subject | Cryptococcus neoformans | en |
| dc.title | 臨床新型隱球菌之分型、交配型、藥物感受性與毒力因子研究 | zh_TW |
| dc.title | Investigation of molecular types, mating types, antifungal susceptibilities and virulence factors in clinical isolates of Cryptococcus neoformans | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 薛博仁,沈偉強,張雅雯 | |
| dc.subject.keyword | 新型隱球菌,分型,毒力因子, | zh_TW |
| dc.subject.keyword | Cryptococcus neoformans,typing,virulence factor, | en |
| dc.relation.page | 79 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2008-08-21 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
| 顯示於系所單位: | 醫學檢驗暨生物技術學系 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf 未授權公開取用 | 1.49 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
